API | danaparoid sodium

danaparoid sodium (orgaran) Report issue

Small molecule Approved ^FDA

AACT ChEMBL DrugBank Drugs@FDA MeSH

Active Ingredient History

NOW

Danaparoid sodium (Orgaran) is an anticoagulant with an antithrombotic action due to inhibition of thrombin generation (TGI) by two mechanisms: indirect inactivation of Factor Xa via AT and direct inhibition of thrombin activation of Factor IX. It also possesses a minor anti-thrombin activity, mediated equally via AT and Heparin Co-factor II producing a ratio of anti-Xa:IIa activity >22. [Meuleman DG. Haemostasis 1992;22:58-65 and Ofosu FA Haemostasis 1992;22:66-72] ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
danaparoid sodium

More Chemistry

Pharmacology

Mechanism of Action:
- Antithrombin-III (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Discontinued
Delivery Methods: Parenteral
Pro Drug: No

Organizations (2)

Research & Development (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)

Thrombocytopenia (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 2
# of Trial Organizations: 2

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue